(080) Exploring Infertility Risk And Semen Parameters In Young Adult Cancer Survivors
D Langston,K Fendereski,J Halpern,I Iko,K Aston,B Emery,J Ramsay,J Horns,J Hotaling
DOI: https://doi.org/10.1093/jsxmed/qdae167.078
2024-12-12
The Journal of Sexual Medicine
Abstract:Introduction Cancer treatment can affect fertility, but assessing infertility risk accurately remains challenging, leading to inconsistent discussions during cancer care. This study aims to assess semen analysis parameters, the gold standard for male fertility evaluation, in young adult oncology patients undergoing fertility preservation interventions post-treatment for the four most common cancers in this age group: testicular, lymphoma, central nervous system (CNS), and melanoma. Objective To examine the impact of common YA oncologic diagnoses on future fertility. Methods We evaluated semen analysis changes in Adolescent Young Adult (AYA) oncology patients, aged 15-39, who underwent fertility evaluation. Using a statewide patient database linked to the Subfertility Health Assisted Reproduction and Environment (SHARE) databases, we identified patients who had one or more semen analyses before and after diagnosis between 1998-2017. Multivariate analyses tested the influence of time from cancer diagnosis and cancer type on semen parameters (concentration, total sperm count, total motility). Results The cohort included 58 individuals, primarily Non-Hispanic White (94.8%), with testis-related conditions being most common (46.6%), followed by lymphoma (24.1%), CNS disorders (20.7%), and melanoma (8.6%). Mean age at diagnosis was 29 years. Semen parameters showed no significant difference post-diagnosis compared to pre-diagnosis, though concentration and total sperm count trended downward. Sperm concentration was significantly lower in the testis diagnosis group mean 17.3 M/mL, SD 13.2) versus CNS (mean 87.8, SD 79.3, P = 0.04), with a trend toward decrease relative to lymphoma and melanoma. Total motility was significantly lower in the testis diagnosis group (mean 50.4%, SD 26.4) versus CNS (mean 65.5%, SD 19.6, P = 0.02) and a trend toward decreased motility relative to the melanoma group (mean 66.5%, SD 17.8, P = 0.09). Conclusions AYA survivors of testis conditions showed decreased semen health parameters compared to other common cancer diagnoses. Fertility discussions with AYA survivors should consider developmental stage and emotional resilience. Multidisciplinary care teams are crucial for offering optimal fertility advice and care given the limited understanding of cancer treatment impacts on fertility outcomes. Disclosure Any of the authors act as a consultant, employee or shareholder of an industry for: StreamDx, Inherent Bioscience, Turtle Health, Maimus, Carrot Fertility.
urology & nephrology